Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Sarcoma 1

Conditions

Neuroblastoma 3Medulloblastoma 3Rhabdomyosarcoma 2Rhabdoid Tumor 2Meningeal Carcinomatosis 2Wilms Tumor 1Sarcoma, Ewing 1Sarcoma 1Retinoblastoma 1Pinealoma 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroectodermal Tumors, Primitive 1Meningeal Neoplasms 1Hepatoblastoma 1Ependymoma 1Desmoplastic Small Round Cell Tumor 1Central Nervous System Neoplasms 1Brain Neoplasms 1

Interventions

Pemetrexed 20Bevacizumab 10Radiotherapy 8Spinal Puncture 7osimertinib 6Methotrexate 6Magnetic Resonance Spectroscopy 6aflutinib 5Topotecan 5Specimen Handling 5Trastuzumab 4Temozolomide 4Radiotherapy, Intensity-Modulated 4Dexamethasone 3trastuzumab deruxtecan 2pembrolizumab 2paclitaxel-Angiopep-2 conjugate 2omburtamab I-131 2merphos 2lorlatinib 2aumolertinib 2WP 744 2Vitamin B 12 2Rituximab 2Radiation 2Folic Acid 2Drug Therapy 2Cytarabine 2Cyclophosphamide 2Capecitabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Meningeal Carcinomatosis × omburtamab I-131 × CNS × Clear all
NCT03275402 2024-02-13

131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases

Y-mAbs Therapeutics

Phase 2/3 Terminated
52 enrolled 11 charts
CNS

Neuroblastoma, Meningeal Carcinomatosis

NCT00089245 2023-12-26

Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer

Y-mAbs Therapeutics

Phase 1 Terminated
177 enrolled
CNSSarcoma

Brain Neoplasms, Medulloblastoma, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor, Meningeal Carcinomatosis, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡